2.2.0.25falsefalse0201 - Disclosure - Nature of Businesstruefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Jan-01-2010_Dec-31-2010http://www.sec.gov/CIK0001113481duration2010-01-01T00:00:002010-12-31T00:00:00USDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170SharesStandardhttp://www.xbrl.org/2003/instancesharesxbrli0USDEPSDividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2true0us-gaap_GeneralPoliciesAbstractus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalseOtherxbrli:stringItemTypestringNo definition available.falsefalse3false0us-gaap_NatureOfOperationsus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged Note 1 - us-gaap:NatureOfOperations-->
<div align="left" style="margin-left: 0%"><!-- XBRL,ns -->
<!-- xbrl,nx -->
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">
</font></b>
</div>
<div style="margin-top: 0pt; font-size: 1pt"></div>
<div align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent">
<b><font style="font-family: 'Times New Roman', Times">
</font></b>
</div>
<div style="margin-top: 12pt; font-size: 1pt"> 
</div>
<table width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #0c1c47; background: transparent; text-align: left">
<tr>
<td width="3%"></td>
<td width="97%"></td>
</tr>
<tr valign="top">
<td>
<b><font style="font-family: 'Times New Roman', Times">1.  </font></b>
</td>
<td>
<b><font style="font-family: 'Times New Roman', Times">Nature of
Business</font></b>
</td>
</tr>
</table>
<div style="margin-top: 6pt; font-size: 1pt"> 
</div>
<div align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 4%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #0c1c47; background: transparent">
The Medicines Company (the Company) is a global pharmaceutical
company focused on advancing the treatment of critical care
patients through the delivery of innovative, cost-effective
medicines to the worldwide hospital marketplace. The Company has
two marketed products,
Angiomax<sup style="font-size: 85%; vertical-align: text-top">®</sup>
(bivalirudin) and
Cleviprex<sup style="font-size: 85%; vertical-align: text-top">®</sup>
(clevidipine butyrate) injectable emulsion, and a pipeline of
acute and intensive care hospital products in development,
including two late-stage development product candidates,
cangrelor and oritavancin, two early stage development product
candidates, MDCO-2010 (formerly known as CU2010) and MDCO-216
(formerly known as ApoA-I Milano), and marketing rights in the
United States and Canada to a
<font style="white-space: nowrap">ready-to-use</font>
formulation of Argatroban for which a new drug application (NDA)
has been submitted to the U.S. Food and Drug Administration
(FDA). The Company believes that Angiomax, Cleviprex and its
products in development possess favorable attributes that
competitive products do not provide, can satisfy unmet medical
needs in the acute and intensive care hospital product market
and offer, or, in the case of the Company’s products in
development, have the potential to offer, improved performance
to hospital businesses.
</div>
</div>
<!--DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd" -->
<!-- Begin Block Tagged NotefalsefalsefalsefalsefalseOtherus-types:textBlockItemTypestringDescribes the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings). Disclosures about the nature of operations need not be quantified; relative importance could be conveyed by use of terms such as "predominately", "about equally", or "major and other". This element is also referred to as "Business Description".Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 94-6
-Paragraph 10
falsefalse12Nature of BusinessUnKnownUnKnownUnKnownUnKnownfalsetrue